PEEK: TSX-V
FULL DISCLOSURE: Peeks Social is an advertising client of AGORA Internet Relations Corp.
Vancouver, British Columbia (FSCwire) – GGX Gold . (TSX-v: GGX), (OTCQB: GGXXF), (FRA: 3SR2) (the “Company†or “GGXâ€) is pleased to announce it has received additional analytical results from its diamond drilling program on the Gold Drop property, located near Greenwood, B.C. Drill core analytical results have been received for 2018 drill holes EVE18-7 to EVE18-18 which tested the area of the Everest Vein, located in the Gold Drop Southwest Zone. The 2018 drilling also tested the COD Vein, located in the Gold Drop Southwest Zone, north of the Everest Vein. The highlight from these analytical results is 12.45 g/t gold and 121 g/t silver over 0.85 meter core length in altered granodiorite in drill hole EVE18-12.
Gold bearing altered granodiorite in drill hole EVE18-12
(12.45g/t Gold over 0.85meters)
To view the graphic in its original size, please click here
The Everest Vein, located south of the COD Vein, was first discovered by Company prospectors during the 2017. Chip samples collected in 2017 across the approximate 0.4 meter wide vein exposure returned up to 52.8 g/t gold and 377 g/t silver while a grab sample of a quartz vein boulder broken off the outcrop by the excavator returned 81.8 g/t gold and 630 g/t silver (News Release of August 21, 2017).
The analytical results listed below are highlights from drill holes EVE18-7 to COD18-18 (intersections greater than 1 g/t gold), testing the area of the Everest Vein. Since true widths cannot be accurately determined from the information available the core lengths (meters) are reported. The gold, silver and tellurium analyses are reported in grams per tonne (g/t).
| Hole ID | From (m) | To (m) | Interval Length (m) | Au (g/t) | Ag (g/t) | Te (g/t) |
| EVE18-10 | 52.34 | 52.97 | 0.63 | 2.72 | 20.7 | 14.9 |
| EVE18-12 | 40.41 | 41.26 | 0.85 | 12.45 | 121 | 91.2 |
| EVE18-12 | 43.65 | 43.90 | 0.25 | 1.42 | 5.57 | 4.48 |
| EVE18-13 | 46.42 | 47.34 | 0.92 | 1.32 | 12.8 | 9.9 |
| EVE18-16 | 18.30 | 19.48 | 1.18 | 1.07 | 9.72 | 8.16 |
| EVE18-16 | 20.09 | 20.72 | 0.63 | 3.00 | 31.2 | 22.0 |
The intersection at 40.41-41.26 meters in drill hole EVE18-12 is altered granodiorite with pyrite. The other intersections listed in the preceding table are altered granodiorite with pyrite and / or veining (quartz and or calcite).
To view the graphic in its original size, please click here
The 2018 drilling program also focused on testing and defining the COD Vein, a Dentonia/Jewel style quartz vein. Trenching during 2017 exposed the northeast – southwest striking COD Vein for over 160 meter strike length. Numerous 2018 drill holes testing the COD Vein intersected significant levels of gold, silver and tellurium as reported in News Releases of May 29, June 14, June 27, July 11, July 19, July 25, August 1, August 9, August 15, August 22, August 30 and September 6. These included holes in the area of the 2017 trench and holes southwest of the 2017 trench. More significant gold intersections (core length) to date from the 2018 program at the COD and Everest veins are as follows:
The Everest Vein 2018 drill holes are located approximately 350 to 800 meters south of the area of 2017 and 2018 COD Vein drill holes.
In addition to the gold discovered by the Company at the COD and Everest veins, gold mineralization is reported in quartz veins in the east and north regions of the property. These include the Gold Drop, North Star and the Silent Friend quartz veins in the east region of the property and Amandy, Roderick Dhu, Lady of the Lake, Lake View and Moonlight in northern region of the property. High grade gold is reported for historic samples at some of these veins with samples reported to exceed 1 oz. / ton gold. Historic gold production occurred at the Gold Drop, North Star, Amandy and Roderick Dhu veins.
Drill core from the 2018 program was geologically logged and sampled. Drill core was sawn in half with half core samples submitted for analysis and remaining half core stored in a secure location. Core samples were delivered to the ALS Minerals laboratory in Vancouver to be analyzed for gold by Fire Assay – AA. Samples exceeding 100 g/t gold were re-analyzed for gold by Fire Assay – Gravimetric Finish. The samples were also analyzed for 48 Elements by Four Acid ICP-MS. Samples exceeding 100 g/t silver were re-analyzed for silver by Four Acid ICP-AES. One sample from COD18-46 exceeded 1500 g/t silver and was re-analyzed for silver by Fire Assay – Gravimetric Finish. Quality control (QC) samples were inserted at regular intervals.
David Martin, P.Geo., a Qualified Person as defined by NI 43-101, is responsible for the technical information contained in this News Release.
To view the Original News release with pictures please go to the website or contact the company.
On Behalf of the Board of Directors,
Barry Brown, Director
604-488-3900
Investor Relations:
Mr. Jack Singh, 604-488-3900Â Â [email protected]
“ We don’t have to do this, we get to do this â€
The Crew
MONTREAL, Sept. 13, 2018 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V:PYR), a TSX Venture 50® high-tech company (the “Company”, the “Corporation†or “PyroGenesis”), a Company that designs, develops and manufactures plasma waste-to-energy systems and plasma torch systems, is pleased to announce today that it has received a milestone payment of $561,600 from HPQ Silicon Resources (“HPQâ€). Furthermore, the recent delivery of the Gen3 PUREVAP™ furnace marks the start of the assembly phase of the pilot plant (the “Plantâ€) in a dedicated area within the production facility at PyroGenesis. The Plant is expected to be completed and operational by mid-year 2019.
The Plant will have an output capacity of 50 tonnes per year, or ~1,000 kg of material per week. This step in the program is the single largest scaling up step and, once successful, will pave the way for an order from HPQ for the first commercial production unit, expected in 2020.
“We’re glad to have reached this new milestone for the project,†said Mr. Pierre Carabin, Chief Technology Officer of PyroGenesis. “We are looking forward to the doors it opens and the opportunities it provides.â€
“We are very excited to move to this final stage of the PUREVAP™ Quartz Reduction Reactor testing program. Now that we have closed all necessary financings, we can focus efforts on the process improvements, scalability, seeking customers, and preparing for commercialization,†said Mr. Bernard J. Tourillon, Chairman, President and CEO of HPQ Silicon. “With these financings closed, our objective going forward will be delivering on the Gen3 PUREVAP™ pilot plant phase with our “Solar Silicon Team†as well as building market awareness of our progress, plans and success.â€
About HPQ Silicon
HPQ Silicon Resources Inc. is a TSX-V listed resource company planning to become a vertically integrated and diversified High Purity, Solar Grade Silicon Metal (SoG Si) producer and a manufacturer of multi and monocrystalline solar cells of the P and N types, required for production of high performance photovoltaic conversion. HPQ goal is to develop, in collaboration with industry leaders, PyroGenesis TSX: PYR and Apollon Solar, that are experts in their fields of interest, the innovative metallurgical PUREVAPTM “Quartz Reduction Reactors (QRR)†process (patent pending), which will permit the transformation and purification of quartz (SiO2) into high purity silicon metal (Si) in one step and reduce by a factor of at least two-third (2/3) the steps required to transform quartz (SiO2) into SoG Si. The pilot plant equipment that will validate the commercial potential of the process is on schedule for mid-2019 start.
About PyroGenesis Canada Inc.
PyroGenesis Canada Inc., a TSX Venture 50® high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2008 certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.
SOURCE PyroGenesis Canada Inc.
For further information please contact: Clémence Bertrand-Bourlaud, Marketing Manager/Investor Relations, Phone: (514) 937-0002, E-mail: [email protected]
RELATED LINKS: http://www.pyrogenesis.com/
MONTREAL, Sept. 13, 2018 – HPQ Silicon Resources Inc (“HPQâ€) (TSX VENTURE:HPQ) (FRANKFURT:UGE) (OTC PINK:URAGF) is pleased to inform shareholders that PyroGenesis Canada Inc (PyroGenesis) (TSX Venture: PYR) has taken delivery of the Gen3 PUREVAPTM “Quartz Reduction Reactor†(“QRRâ€) furnace, a key component of the pilot equipment. Furthermore, HPQ has made another milestone payment of $561,600 to PyroGenesis.  Since August 2016, HPQ has invested $3,988,400 for the pilot equipment, representing 90% of the $4,430,000 design, fabrication and assembly budget. Delivery of the furnace marks the start of the assembly phase of the Pilot Plant in an HPQ – dedicated area at the production facility of PyroGenesis in Montréal.  The Pilot Plant assembly will be completed during Q1 2019, commissioned during Q2 2019 and operational mid – 2019, only 3 years after the original concept was validated.
VALIDATING COMMERCIAL SCALABILITY OF INNOVATION REQUIRES FOCUS AND FLEXIBILITY
The Pilot Plant will have an output capacity of 50 tonnes per year, or ~ 1,000 kg of material per week. Â This step in the program is the single largest scaling up step and, once successful, will pave the way for the order of HPQ first commercial production unit, planned for 2020.
Using the data generated by the Gen2 PUREVAPTM tests and Apollon Solar technical knowhow, HPQ and PyroGenesis will continue to look for ways of optimizing our approach of validating the commercial scalability of the process while mitigating the technical and commercial risks associated with the project.
Bernard J. Tourillon, Chairman, President and CEO of HPQ Silicon stated, “We are very excited to move to this final stage of the PUREVAP™ QRR testing program.  Now that we have closed all necessary financings, we can focus efforts on the process improvements, scalability, seeking customers, and preparing for commercialization. With these financings closed, our objective going forward will be delivering on the Gen3 PUREVAP™ Pilot Plant phase with our “Solar Silicon Team†as well as building market awareness of our progress, plans and success.â€
This Press Release Is Available On The Company’s CEO Verified Discussion Forum, A Moderated Social Media Platform That Enables Civilized Discussion and Q&A’s Between Management and Shareholders.  https://agoracom.com/ir/HPQ-SiliconResources/forums/discussion
About HPQ Silicon
HPQ Silicon Resources Inc. is a TSX-V listed resource company planning to become a vertically integrated and diversified High Purity, Solar Grade Silicon Metal (SoG Si) producer and a manufacturer of multi and monocrystalline solar cells of the P and N types, required for production of high performance photovoltaic conversion.
HPQ’s goal is to develop, in collaboration with industry leaders, PyroGenesis (TSX-V: PYR) and Apollon Solar, that are experts in their fields of interest, the innovative metallurgical PUREVAPTM “Quartz Reduction Reactors (QRR)†process (patent pending), which will permit the transformation and purification of quartz (SiO2) into high purity silicon metal (Si) in one step and reduce by a factor of at least two-thirds (2/3) the steps required to transform quartz (SiO2) into SoG Si. The pilot plant equipment that will validate the commercial potential of the process is on schedule to start mid-2019.
Disclaimers:
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information contact
Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011
Patrick Levasseur, COO Tel: (514) 262-9239
www.HPQSilicon.com
Shares outstanding: 222, 284,053Â
ORLEANS, Ontario, Sept. 13, 2018 – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that Health Canada has re-classified the inhalation pipe device used in the delivery of its PPP001 cannabis drug to a Class 2 Medical Device. The reclassification will help pave the way towards reimbursement for patients; a key element to patient access and care. The significance of this decision is such that if PPP001 is approved by Health Canada, both the prescription drug and the inhalation device will be eligible for insurance coverage by private and provincial public insurance plans. Tetra Bio-Pharma is undertaking a Phase III trial with PPP001 treating late stage cancer patients looking to improve quality of life and reduce pain. The Company also recently announced it is starting a head to head trial to investigate cannabis versus Fentanyl in managing breakthrough cancer pain.
“We are very excited by the reclassification as we believe it will provide patients with a financial benefit in terms of coverage for the device and prescription drug,†stated Dr. Guy Chamberland, Ph.D., Interim CEO and CSO at Tetra Bio-Pharma. “Many cancer patients rely on private and public insurance plans for access to their medication. This decision by the Government of Canada is an important step forward to facilitating access to cannabis drugs. This coupled with our robust clinical trial program and the evidence we are establishing will support physicians in discussing and recommending this option with their patients.â€
Dr. Chamberland further stated, “the lack of scientific data on the safety and efficacy of cannabis is a critical barrier to patient access, and something that Canadian physicians are waiting for before being comfortable to prescribe it. Equally essential is adhering to the highest standards of drug manufacturing as well as the production of the delivery mechanism – something that Tetra is committed to. There are more than 300,000 registered users of medical cannabis in the country and we can only expect this number to rise.â€
Tetra has been a pioneer in the development of several cannabis drugs. To date, the Corporation has completed several safety and pharmacokinetic studies in healthy volunteers obtaining proper dosing information and a clear understanding of the potential cardiovascular and neurological risks to patients. This information is critical to protect public health, and Tetra Bio-Pharma is engaged with Health Canada to comply with the highest drug safety standards.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001, insurance coverage for products being developed, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
| Media Contact | |
| Energi PR | |
| Carol Levine | Stephanie Engel |
| 514-288-8500 ext. 226 | 416-425-9143 ext. 209 |
| [email protected] | [email protected] |
John E. Mulhall Brand Contributor
What if everyone involved in a financial transaction could share the same ledger—and it was always up to date? No need for reconciliations, with simultaneous settlements immediately available to all participants, and instant visibility into accounts receivable, the supply chain and virtually all relevant transactions.
Formally, blockchain is a digital ledger technology (DLT), which focuses on recording and storing transactions of any type in a shared platform.iStock
Indeed, what if there was just one, unimpeachable version of the truth? That is the promise of blockchain technology.
While blockchain is often mentioned in conjunction with cyptocurrency platforms like Bitcoin, the underlying technology goes way beyond those nascent digital currencies. Formally, blockchain is a digital ledger technology (DLT), which focuses on recording and storing transactions of any type in a shared platform.
What Is a Blockchain?
As the word suggests, a blockchain is a series of connected blocks, or boxes. Each block contains data involved in a specific transaction. As each transaction occurs, it is stored in a block and added to the chain. Together, the blocks form a distributed database that can hold a growing number of records—a blockchain.
But unlike a traditional database, in which information resides in unique repositories across multiple partners and must ultimately be reconciled, the distributed blockchain database creates a single, shared digital ledger.
To protect the integrity of data, each block must be validated by every participant and secured using electronic cryptography. Changes cannot be made without the approval of participants. Think of it as having a notary there to verify every transaction. This chronological chain of transactions thus provides a single source of secured, up-to-date information that all authorized parties can share.
For a quick explanation of how blockchain works, read Blockchain and the Future of Finance.
A Finance Windfall
The potential benefits for CFOs and their finance teams are compelling: New levels of data transparency, faster access to information and features like “smart contracts†will bring significant changes to financial operations. Among other things, the recent report from KPMG analysts identified the following benefits:
A New Future for CFOs
Blockchain is also going to have significant impact on financial operations. The KPMG analysts who have been studying the technology anticipate these key trends:
Evaluating Blockchain for Your Business
Blockchain will have a big impact on core processes: Quote-to-cash, source-to-pay, and acquire-to-retire processes will all be affected.
But blockchain is not the latest new cure-all. It’s important for CFOs and executive leaders to address a number of questions about when and how blockchain implementation makes sense for their businesses, including:
KPMG’s Financial Management practice and Digital Ledger Services team have developed a framework to facilitate answering these questions. To prepare for this new world, they can help you evaluate the role that blockchain can serve in your organization. To learn more, download their special report, Blockchain and the Future of Finance.
Source: https://www.forbes.com/sites/kpmg/2018/09/11/blockchain-and-the-future-of-finance/#4f5ac94f620f
TORONTO, Sept. 11, 2018 — Star Navigation Systems Group Ltd. (CSE:SNA) (CSE:SNA.CN) (OTCQB:SNAVF) (“Star†or the “Companyâ€) is pleased to provide shareholders with the following comprehensive update.
BOMBARDER JOINT RESEARCH AND DEVELOPMENT PROGRAM
Star is pleased to confirm that the joint research and development program with Bombardier and other industrials and universities of Canada is progressing very positively. The STAR-A.D.S. ® system which is at the heart of the program, after having been validated and extensively used by the aircraft manufacturer, has now been transferred to another flight test vehicle to complete the flight testing and the data collection.
EMERGENCY MEDICAL SERVICES APPLICATIONS
Star’s Land System Aided Medical Monitoring system (“STAR-LSAMM™â€) for ground ambulance applications has undergone a series of demonstrations by a care organization in North America. Its airborne parent system, the In-Flight System Aided Medical Monitoring system (STAR-ISAMM™â€), has now been demonstrated to several stakeholders of the commercial and civil air ambulance market.
STAR-A.D.S. ® KINGDOM OF SAUDI ARABIA
The STAR-A.D.S. ® system, which recently earned its FAA certification, has been validated on an Airbus aircraft and is now expecting its General Authority of Civil Aviation of the Kingdom of Saudi Arabia. The first flying system in the Gulf becomes our local ‘showcase on real-time tracking, monitoring and GADSS compliance.
STAR M.M.I. ™ ASIA AND FURTHER QUALIFICATIONS
STAR M.M.I. ™ has successfully submitted a proposal to a new Asian customer for military displays retrofit program to start in November this year.
STAR which is already ASI9100D qualified – the latest standard for aerospace activities – and authorized to work on military programs under the Canadian Controlled goods program, is undertaking steps to have its quality management system qualified for medical equipment.
This Press Release Is Available On The Company’s CEO Verified Discussion Forum, A Moderated Social Media Platform That Enables Civilized Discussion and Q&A Between Management and Shareholders.
https://agoracom.com/ir/StarNavigationSystems/forums/discussion
About Star Navigation:
Star Navigation Systems Group Ltd. owns the exclusive worldwide license to its proprietary, patented In-flight Safety Monitoring System, STAR-ISMS®, the heart of the STAR-A.D.S. ® System. Its real-time capability of tracking performance trends and predicting incident-occurrence enhances aviation safety and improves fleet management while reducing costs for the operator.
Stars’ M.M.I. Division designs and manufactures high performance, mission critical, flight deck flat panel displays for defence and commercial aviation industries worldwide. These displays are found on aircraft and simulators, from P-3 Orion and C-130 aircraft, to Sikorsky and AgustaWestland helicopters, as examples.
Certain statements contained in this News Release constitute forward-looking statements. When used in this document, the words “mayâ€, “wouldâ€, “couldâ€, “willâ€, “expected†and similar expressions, as they relate to Star or its management are intended to identify forward-looking statements. Such statements reflect Star’s current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause Star’s actual performance or achievements to vary from those described herein. Should one or more of these factors or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Star does not assume any obligation to update these forward-looking statements, except as required by law.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of the content of this release.
Please visit www.star-navigation.com or
Jean-Louis Larmor, (416) 252-2889 Ext. 221
C.O.O.
Why Kuuhubb?
FULL DISCLOSURE: Kuuhubb is an advertising client of AGORA Internet Relations Corp.
ORLEANS, Ontario, Sept. 11, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that it is accelerating the submission of a pre-marketing application for the registration of its cannabis drugs PPP001 and PPP005 under Directive 2001/83/EC of the European Parliament and of the Council.
This directive provides Tetra Bio-Pharma with the legal and regulatory framework needed to submit its pre-marketing application for its cannabis drugs. According to Dr. Guy Chamberland, Interim CEO and CSO, “the corporation has performed its own clinical trials and has sufficient quality and clinical trial data to initiate the application for the registration of PPP001 and PPP005 under the Directive 2001/83/EC. Tetra intends to pursue a Full Market Authorisation since it has a dossier supporting the medicinal product’s quality, safety, and efficacy.â€
All of Tetra’s clinical trials were performed with the same quality of evidence required by the National Competent authorities approving medicines/drugs. Tetra has completed several well-designed safety, pharmacodynamic and pharmacokinetic studies in healthy volunteers and also has two ongoing, well-designed clinical trials in patients. These trials are all double-blind, randomized and placebo controlled.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001 and/or PPP005 by the European Medicines Agency, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
| Media Contact | |
| Energi PR | |
| Carol Levine | Stephanie Engel |
| 514-288-8500 ext. 226 | 416-425-9143 ext. 209 |
| [email protected] | [email protected] |
